Following concerns from our community, Roche have issued the following statement about supply and availability of Hemlibra:
We understand the interest in Hemlibra▼(emicizumab) for people with haemophilia A and are committed to ensuring adequate supply amid the queries around how the coronavirus might impact availability of Hemlibra.
To date, Hemlibra has been manufactured at Chugai’s sites in Japan. In line with common practice to ensure supply continuity of its medicines, Roche is also producing Hemlibra at an alternative site outside of Japan. Our global manufacturing network has robust plans for dealing with the impact of potential health and other global crises.
As of now, we have not identified any critical component that would impact our ability to supply Hemlibra in the future, based on current demand forecasts. Logistics (shipments) are also stable at this point in time.
We are actively assessing and monitoring the situation and any potential impact to our supply chain. Should we become aware of any change to the supply or availability of Hemlibra at any point, we will inform the haemophilia community.
If you have any questions about this, please contact your haemophilia centre or email firstname.lastname@example.org